Consequently, larotrectinib and entrectinib have been granted tumor-agnostic FDA approvals and selpercatinib and pralsetinib are approved for both NSCLC and papillary or medullary thyroid cancers with RET fusions or mutations, respectively. The gene discussed is RET; the disease is non-small cell lung carcinoma.